Skip Navigation

Geoffrey R. Oxnard, MD


Medical Oncology

Make an Appointment
Watch Video

Physician

  • Physician
  • Associate Professor of Medicine, Harvard Medical School

Centers/Programs

Clinical Interests

  • Acquired resistance to EGFR inhibitors
  • Liquid biopsies
  • Lung cancer genotyping and rare genotypes

Diseases Treated

  • Lung Cancer, non-small cell
  • Lung Cancer, small cell

Contact Information

  • Appointments877-332-4294 (new)
    617-632-6190 (established)
  • Office Phone Number617-632-6049
  • Fax617-632-5786

Bio

I am a medical oncologist specializing in the treatment of patients with non-small cell lung cancer. My research focuses on strategies for improved understanding and treatment of lung cancer. I have several specific areas of research focus, which include:

  • Acquired resistance to targeted therapies (EGFR, ALK, etc) in lung cancer
  • Targeted therapies and clinical trial design for rare lung cancer genotypes
  • The biology of lung cancer diagnosed at a young age (under the age of 50)
  • Familial lung cancer in non-smokers
  • Noninvasive lung cancer genotyping through analysis of free floating DNA in the blood
     

Board Certification:

  • Internal Medicine, 2008
  • Medical Oncology, 2010

Fellowship:

  • Memorial Sloan Kettering Cancer Center, Medical Oncology

Residency:

  • Massachusetts General Hospital, Internal Medicine

Medical School:

  • University of Chicago Pritzker School of Medicine

Recent Awards:

  • Ascelpios Award, Bonnie J. Addario Lung Cancer Foundation 2014
  • Ellen and Stephen Fine Teaching Award, Dana-Farber Cancer Institute 2013
  • Career Development Award, Conquer Cancer Foundation of ASCO 2012
  • Young Investigator Award, ASCO Cancer Foundation, 2010; Merit Award, ASCO Annual Meeting, 2010 2010

Research

Oxnard GR, Hu Y, Mileham KF, Husain H, Costa DB, Tracy P, Feeney N, Sholl LM, Dahlberg SE, Redig AJ, Kwiatkowski DJ, Rabin MS, Paweletz CP, Thress KS, Jänne PA. Assessment of Resistance Mechanisms and Clinical Implications in Patients With EGFR T790M-Positive Lung Cancer and Acquired Resistance to Osimertinib. JAMA Oncol. 2018 Aug 02.
View in: PubMed

Oxnard GR, Paweletz CP. Regarding the Congruence Between 2 Circulating Tumor DNA Sequencing Assays. JAMA Oncol. 2018 Jul 19.
View in: PubMed

Guibert N, Tsukada H, Hwang DH, Chambers E, Cibas ES, Bale T, Supplee J, Ulrich B, Sholl LM, Paweletz CP, Oxnard GR. Liquid biopsy of fine-needle aspiration supernatant for lung cancer genotyping. Lung Cancer. 2018 Aug; 122:72-75.
View in: PubMed

Camidge DR, Sequist LV, Jänne PA, Weickhardt AJ, Dowling ES, Alicea J, Fan J, Oxnard GR. Phase Ib Study of High-dose Intermittent Afatinib in Patients With Advanced Solid Tumors. Clin Lung Cancer. 2018 May 05.
View in: PubMed

Guibert N, Hu Y, Feeney N, Kuang Y, Plagnol V, Jones G, Howarth K, Beeler JF, Paweletz CP, Oxnard GR. Amplicon-based next-generation sequencing of plasma cell-free DNA for detection of driver and resistance mutations in advanced non-small cell lung cancer. Ann Oncol. 2018 Apr 01; 29(4):1049-1055.
View in: PubMed

Hu Y, Ulrich BC, Supplee J, Kuang Y, Lizotte PH, Feeney NB, Guibert NM, Awad MM, Wong KK, Jänne PA, Paweletz CP, Oxnard GR. False-Positive Plasma Genotyping Due to Clonal Hematopoiesis. Clin Cancer Res. 2018 Mar 22.
View in: PubMed

Merker JD, Oxnard GR, Compton C, Diehn M, Hurley P, Lazar AJ, Lindeman N, Lockwood CM, Rai AJ, Schilsky RL, Tsimberidou AM, Vasalos P, Billman BL, Oliver TK, Bruinooge SS, Hayes DF, Turner NC. Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review. J Clin Oncol. 2018 Jun 01; 36(16):1631-1641.
View in: PubMed

Merker JD, Oxnard GR, Compton C, Diehn M, Hurley P, Lazar AJ, Lindeman N, Lockwood CM, Rai AJ, Schilsky RL, Tsimberidou AM, Vasalos P, Billman BL, Oliver TK, Bruinooge SS, Hayes DF, Turner NC. Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review. Arch Pathol Lab Med. 2018 Mar 05.
View in: PubMed

Kuang Y, O'Connell A, Sacher AG, Feeney N, Alden RS, Oxnard GR, Paweletz CP. Monitoring of Response and Resistance in Plasma of EGFR-Mutant Lung Cancer Using Droplet Digital PCR. Methods Mol Biol. 2018; 1768:193-207.
View in: PubMed

Yu HA, Spira A, Horn L, Weiss J, West H, Giaccone G, Evans T, Kelly RJ, Desai B, Krivoshik A, Moran D, Poondru S, Jie F, Aoyama K, Keating A, Oxnard GR. A Phase I, Dose Escalation Study of Oral ASP8273 in Patients with Non-small Cell Lung Cancers with Epidermal Growth Factor Receptor Mutations. Clin Cancer Res. 2017 Dec 15; 23(24):7467-7473.
View in: PubMed

Hu Y, Alden RS, Odegaard JI, Fairclough SR, Chen R, Heng J, Feeney N, Nagy RJ, Shah J, Ulrich B, Gutierrez M, Lanman RB, Garber JE, Paweletz CP, Oxnard GR. Discrimination of Germline EGFR T790M Mutations in Plasma Cell-Free DNA Allows Study of Prevalence Across 31,414 Cancer Patients. Clin Cancer Res. 2017 Dec 01; 23(23):7351-7359.
View in: PubMed

Martínez P, Mak RH, Oxnard GR. Targeted Therapy as an Alternative to Whole-Brain Radiotherapy in EGFR-Mutant or ALK-Positive Non-Small-Cell Lung Cancer With Brain Metastases. JAMA Oncol. 2017 Sep 01; 3(9):1274-1275.
View in: PubMed

Leonardi GC, Oxnard GR, Haas A, Lang JP, Williams JS, Awad MM. Diabetic Ketoacidosis as an Immune-related Adverse Event from Pembrolizumab in Non-Small Cell Lung Cancer. J Immunother. 2017 Jul/Aug; 40(6):249-251.
View in: PubMed

Sacher AG, Komatsubara KM, Oxnard GR. Application of Plasma Genotyping Technologies in Non-Small Cell Lung Cancer: A Practical Review. J Thorac Oncol. 2017 Sep; 12(9):1344-1356.
View in: PubMed

Oxnard GR, Paweletz CP, Sholl LM. Genomic Analysis of Plasma Cell-Free DNA in Patients With Cancer. JAMA Oncol. 2017 Jun 01; 3(6):740-741.
View in: PubMed

Kosaka T, Tanizaki J, Paranal RM, Endoh H, Lydon C, Capelletti M, Repellin CE, Choi J, Ogino A, Calles A, Ercan D, Redig AJ, Bahcall M, Oxnard GR, Eck MJ, Jänne PA. Response Heterogeneity of EGFR and HER2 Exon 20 Insertions to Covalent EGFR and HER2 Inhibitors. Cancer Res. 2017 05 15; 77(10):2712-2721.
View in: PubMed

Aerts HJ, Grossmann P, Tan Y, Oxnard GR, Rizvi N, Schwartz LH, Zhao B. Corrigendum: Defining a Radiomic Response Phenotype: A Pilot Study using targeted therapy in NSCLC. Sci Rep. 2017 02 17; 7:41197.
View in: PubMed

Sholl LM, Do K, Shivdasani P, Cerami E, Dubuc AM, Kuo FC, Garcia EP, Jia Y, Davineni P, Abo RP, Pugh TJ, van Hummelen P, Thorner AR, Ducar M, Berger AH, Nishino M, Janeway KA, Church A, Harris M, Ritterhouse LL, Campbell JD, Rojas-Rudilla V, Ligon AH, Ramkissoon S, Cleary JM, Matulonis U, Oxnard GR, Chao R, Tassell V, Christensen J, Hahn WC, Kantoff PW, Kwiatkowski DJ, Johnson BE, Meyerson M, Garraway LA, Shapiro GI, Rollins BJ, Lindeman NI, MacConaill LE. Institutional implementation of clinical tumor profiling on an unselected cancer population. JCI Insight. 2016 Nov 17; 1(19):e87062.
View in: PubMed

Klein JP, Stover DG, Oxnard GR, Levy BD, Loscalzo J. Restoring Balance: Paraneoplastic Cerebellar Degeneration. Am J Med. 2017 Mar; 130(3):e85-e87.
View in: PubMed

Bahcall M, Sim T, Paweletz CP, Patel JD, Alden RS, Kuang Y, Sacher AG, Kim ND, Lydon CA, Awad MM, Jaklitsch MT, Sholl LM, Jänne PA, Oxnard GR. Acquired METD1228V Mutation and Resistance to MET Inhibition in Lung Cancer. Cancer Discov. 2016 12; 6(12):1334-1341.
View in: PubMed

Gitlitz B, Addario B, Sable-Hunt A, Novello S, Vavala T, Chen R, Bittoni M, Park SL, Jennings M, Oxnard G. PD1.05 (also presented as P1.49): The Genomics of Young Emergent Lung Cancer. J Thorac Oncol. 2016 Oct; 11(10S):S174.
View in: PubMed

Gitlitz B, Addario B, Sable-Hunt A, Novello S, Vavala T, Chen R, Bittoni M, Park SL, Jennings M, Oxnard G. P1.49 (also presented as PD1.05): The Genomics of Young Emergent Lung Cancer: Track: Advanced NSCLC. J Thorac Oncol. 2016 Oct; 11(10S):S214.
View in: PubMed

Aerts HJ, Grossmann P, Tan Y, Oxnard GR, Rizvi N, Schwartz LH, Zhao B. Defining a Radiomic Response Phenotype: A Pilot Study using targeted therapy in NSCLC. Sci Rep. 2016 09 20; 6:33860.
View in: PubMed

Lampson BL, Nishino M, Dahlberg SE, Paul D, Santos AA, Jänne PA, Oxnard GR. Activity of erlotinib when dosed below the maximum tolerated dose for EGFR-mutant lung cancer: Implications for targeted therapy development. Cancer. 2016 Aug 15.
View in: PubMed

Sacher AG, Alden RS, Oxnard GR. Early Intervention in Lung Cancers With Rapid Plasma Genotyping for EGFR and KRAS Mutations-Reply. JAMA Oncol. 2016 08 01; 2(8):1096-7.
View in: PubMed

Sacher AG, Paweletz C, Dahlberg SE, Alden RS, O'Connell A, Feeney N, Mach SL, Jänne PA, Oxnard GR. Prospective Validation of Rapid Plasma Genotyping for the Detection of EGFR and KRAS Mutations in Advanced Lung Cancer. JAMA Oncol. 2016 Aug 01; 2(8):1014-22.
View in: PubMed

Reckamp KL, Melnikova VO, Karlovich C, Sequist LV, Camidge DR, Wakelee H, Perol M, Oxnard GR, Kosco K, Croucher P, Samuelsz E, Vibat CR, Guerrero S, Geis J, Berz D, Mann E, Matheny S, Rolfe L, Raponi M, Erlander MG, Gadgeel S. A Highly Sensitive and Quantitative Test Platform for Detection of NSCLC EGFR Mutations in Urine and Plasma. J Thorac Oncol. 2016 Oct; 11(10):1690-700.
View in: PubMed

Oxnard GR, Thress KS, Alden RS, Lawrance R, Paweletz CP, Cantarini M, Yang JC, Barrett JC, Jänne PA. Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non-Small-Cell Lung Cancer. J Clin Oncol. 2016 Oct 01; 34(28):3375-82.
View in: PubMed

Yanagita M, Redig AJ, Paweletz CP, Dahlberg SE, O'Connell A, Feeney N, Taibi M, Boucher D, Oxnard GR, Johnson BE, Costa DB, Jackman DM, Jänne PA. A Prospective Evaluation of Circulating Tumor Cells and Cell-Free DNA in EGFR-Mutant Non-Small Cell Lung Cancer Patients Treated with Erlotinib on a Phase II Trial. Clin Cancer Res. 2016 Dec 15; 22(24):6010-6020.
View in: PubMed

Oxnard GR, Wilcox KH, Gonen M, Polotsky M, Hirsch BR, Schwartz LH. Response Rate as a Regulatory End Point in Single-Arm Studies of Advanced Solid Tumors. JAMA Oncol. 2016 Jun 01; 2(6):772-9.
View in: PubMed

Ahn MJ, Yang J, Yu H, Saka H, Ramalingam S, Goto K, Kim SW, Yang L, Walding A, Oxnard GR. 136O: Osimertinib combined with durvalumab in EGFR-mutant non-small cell lung cancer: Results from the TATTON phase Ib trial. J Thorac Oncol. 2016 Apr; 11(4 Suppl):S115.
View in: PubMed

Oxnard GR, Thress KS, Alden RS, Lawrance R, Paweletz CP, Cantarini M, Barrett C, Yang J, Jänne P. 135O_PR: Plasma genotyping for predicting benefit from osimertinib in patients (pts) with advanced NSCLC. J Thorac Oncol. 2016 Apr; 11(4 Suppl):S154.
View in: PubMed

Oxnard GR. The cellular origins of drug resistance in cancer. Nat Med. 2016 Mar; 22(3):232-4.
View in: PubMed

Sacher AG, Dahlberg SE, Heng J, Mach S, Jänne PA, Oxnard GR. Association Between Younger Age and Targetable Genomic Alterations and Prognosis in Non-Small-Cell Lung Cancer. JAMA Oncol. 2016 Mar; 2(3):313-20.
View in: PubMed

Awad MM, Oxnard GR, Jackman DM, Savukoski DO, Hall D, Shivdasani P, Heng JC, Dahlberg SE, Jänne PA, Verma S, Christensen J, Hammerman PS, Sholl LM. MET Exon 14 Mutations in Non-Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression. J Clin Oncol. 2016 Mar 01; 34(7):721-30.
View in: PubMed

Govindan R, Mandrekar SJ, Gerber DE, Oxnard GR, Dahlberg SE, Chaft J, Malik S, Mooney M, Abrams JS, Jänne PA, Gandara DR, Ramalingam SS, Vokes EE. ALCHEMIST Trials: A Golden Opportunity to Transform Outcomes in Early-Stage Non-Small Cell Lung Cancer. Clin Cancer Res. 2015 Dec 15; 21(24):5439-44.
View in: PubMed

Calles A, Liao X, Sholl LM, Rodig SJ, Freeman GJ, Butaney M, Lydon C, Dahlberg SE, Hodi FS, Oxnard GR, Jackman DM, Jänne PA. Expression of PD-1 and Its Ligands, PD-L1 and PD-L2, in Smokers and Never Smokers with KRAS-Mutant Lung Cancer. J Thorac Oncol. 2015 Dec; 10(12):1726-35.
View in: PubMed

Gao X, Sholl LM, Nishino M, Heng JC, Jänne PA, Oxnard GR. Clinical Implications of Variant ALK FISH Rearrangement Patterns. J Thorac Oncol. 2015 Nov; 10(11):1648-52.
View in: PubMed

Paweletz CP, Sacher AG, Raymond CK, Alden RS, O'Connell A, Mach SL, Kuang Y, Gandhi L, Kirschmeier P, English JM, Lim LP, Jänne PA, Oxnard GR. Bias-Corrected Targeted Next-Generation Sequencing for Rapid, Multiplexed Detection of Actionable Alterations in Cell-Free DNA from Advanced Lung Cancer Patients. Clin Cancer Res. 2016 Feb 15; 22(4):915-22.
View in: PubMed

Alden RS, Mandrekar SJ, Oxnard GR. Designing a definitive trial for adjuvant targeted therapy in genotype defined lung cancer: the ALCHEMIST trials. Chin Clin Oncol. 2015 Sep; 4(3):37.
View in: PubMed

Oxnard GR, Watt C, Wigle D, Boughey JC. Biomarker-driven adjuvant targeted therapy for NSCLC-the ALCHEMIST trials. Bull Am Coll Surg. 2015 Sep; 100(9):25-7.
View in: PubMed

Tanizaki J, Ercan D, Capelletti M, Dodge M, Xu C, Bahcall M, Tricker EM, Butaney M, Calles A, Sholl LM, Hammerman PS, Oxnard GR, Wong KK, Jänne PA. Identification of Oncogenic and Drug-Sensitizing Mutations in the Extracellular Domain of FGFR2. Cancer Res. 2015 Aug 01; 75(15):3139-46.
View in: PubMed

Van Allen EM, Golay HG, Liu Y, Koyama S, Wong K, Taylor-Weiner A, Giannakis M, Harden M, Rojas-Rudilla V, Chevalier A, Thai T, Lydon C, Mach S, Avila AG, Wong JA, Rabin AR, Helmkamp J, Sholl L, Carter SL, Oxnard G, Janne P, Getz G, Lindeman N, Hammerman PS, Garraway LA, Hodi FS, Rodig SJ, Dranoff G, Wong KK, Barbie DA. Long-term Benefit of PD-L1 Blockade in Lung Cancer Associated with JAK3 Activation. Cancer Immunol Res. 2015 Aug; 3(8):855-63.
View in: PubMed

Thress KS, Paweletz CP, Felip E, Cho BC, Stetson D, Dougherty B, Lai Z, Markovets A, Vivancos A, Kuang Y, Ercan D, Matthews SE, Cantarini M, Barrett JC, Jänne PA, Oxnard GR. Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M. Nat Med. 2015 Jun; 21(6):560-2.
View in: PubMed

Sequist LV, Soria JC, Goldman JW, Wakelee HA, Gadgeel SM, Varga A, Papadimitrakopoulou V, Solomon BJ, Oxnard GR, Dziadziuszko R, Aisner DL, Doebele RC, Galasso C, Garon EB, Heist RS, Logan J, Neal JW, Mendenhall MA, Nichols S, Piotrowska Z, Wozniak AJ, Raponi M, Karlovich CA, Jaw-Tsai S, Isaacson J, Despain D, Matheny SL, Rolfe L, Allen AR, Camidge DR. Rociletinib in EGFR-mutated non-small-cell lung cancer. N Engl J Med. 2015 Apr 30; 372(18):1700-9.
View in: PubMed

Lo PC, Dahlberg SE, Nishino M, Johnson BE, Sequist LV, Jackman DM, Jänne PA, Oxnard GR. Delay of treatment change after objective progression on first-line erlotinib in epidermal growth factor receptor-mutant lung cancer. Cancer. 2015 Aug 01; 121(15):2570-7.
View in: PubMed

Gerber DE, Oxnard GR, Govindan R. ALCHEMIST: Bringing genomic discovery and targeted therapies to early-stage lung cancer. Clin Pharmacol Ther. 2015 May; 97(5):447-50.
View in: PubMed

Oxnard GR. Commentary. Clin Chem. 2015 Apr; 61(4):586-7.
View in: PubMed

Castellanos-Rizaldos E, Paweletz C, Song C, Oxnard GR, Mamon H, Jänne PA, Makrigiorgos GM. Enhanced ratio of signals enables digital mutation scanning for rare allele detection. J Mol Diagn. 2015 May; 17(3):284-92.
View in: PubMed

Calles A, Sholl LM, Rodig SJ, Pelton AK, Hornick JL, Butaney M, Lydon C, Dahlberg SE, Oxnard GR, Jackman DM, Jänne PA. Immunohistochemical Loss of LKB1 Is a Biomarker for More Aggressive Biology in KRAS-Mutant Lung Adenocarcinoma. Clin Cancer Res. 2015 Jun 15; 21(12):2851-60.
View in: PubMed

Yu HA, Sima CS, Shen R, Kass S, Gainor J, Shaw A, Hames M, Iams W, Aston J, Lovly CM, Horn L, Lydon C, Oxnard GR, Kris MG, Ladanyi M, Riely GJ. Prognostic impact of KRAS mutation subtypes in 677 patients with metastatic lung adenocarcinomas. J Thorac Oncol. 2015 Mar; 10(3):431-7.
View in: PubMed

Jenkins RW, Oxnard GR, Elkin S, Sullivan EK, Carter JL, Barbie DA. Response to Crizotinib in a Patient With Lung Adenocarcinoma Harboring a MET Splice Site Mutation. Clin Lung Cancer. 2015 Sep; 16(5):e101-4.
View in: PubMed

Jänne PA, Ou SH, Kim DW, Oxnard GR, Martins R, Kris MG, Dunphy F, Nishio M, O'Connell J, Paweletz C, Taylor I, Zhang H, Goldberg Z, Mok T. Dacomitinib as first-line treatment in patients with clinically or molecularly selected advanced non-small-cell lung cancer: a multicentre, open-label, phase 2 trial. Lancet Oncol. 2014 Dec; 15(13):1433-41.
View in: PubMed

Luke JJ, Oxnard GR, Paweletz CP, Camidge DR, Heymach JV, Solit DB, Johnson BE. Realizing the potential of plasma genotyping in an age of genotype-directed therapies. J Natl Cancer Inst. 2014 Aug; 106(8).
View in: PubMed

Parikh RB, Cronin AM, Kozono DE, Oxnard GR, Mak RH, Jackman DM, Lo PC, Baldini EH, Johnson BE, Chen AB. Definitive primary therapy in patients presenting with oligometastatic non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2014 Jul 15; 89(4):880-7.
View in: PubMed

Sacher AG, Jänne PA, Oxnard GR. Management of acquired resistance to epidermal growth factor receptor kinase inhibitors in patients with advanced non-small cell lung cancer. Cancer. 2014 Aug 01; 120(15):2289-98.
View in: PubMed

Oxnard GR, Paweletz CP, Kuang Y, Mach SL, O'Connell A, Messineo MM, Luke JJ, Butaney M, Kirschmeier P, Jackman DM, Jänne PA. Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA. Clin Cancer Res. 2014 Mar 15; 20(6):1698-1705.
View in: PubMed

Yasuda H, Park E, Yun CH, Sng NJ, Lucena-Araujo AR, Yeo WL, Huberman MS, Cohen DW, Nakayama S, Ishioka K, Yamaguchi N, Hanna M, Oxnard GR, Lathan CS, Moran T, Sequist LV, Chaft JE, Riely GJ, Arcila ME, Soo RA, Meyerson M, Eck MJ, Kobayashi SS, Costa DB. Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer. Sci Transl Med. 2013 Dec 18; 5(216):216ra177.
View in: PubMed

Oxnard GR, Nguyen KS, Costa DB. Germline mutations in driver oncogenes and inherited lung cancer risk independent of smoking history. J Natl Cancer Inst. 2014 Jan; 106(1):djt361.
View in: PubMed

Brunner AM, Costa DB, Heist RS, Garcia E, Lindeman NI, Sholl LM, Oxnard GR, Johnson BE, Hammerman PS. Treatment-related toxicities in a phase II trial of dasatinib in patients with squamous cell carcinoma of the lung. J Thorac Oncol. 2013 Nov; 8(11):1434-7.
View in: PubMed

Goldberg SB, Oxnard GR, Digumarthy S, Muzikansky A, Jackman DM, Lennes IT, Sequist LV. Chemotherapy with Erlotinib or chemotherapy alone in advanced non-small cell lung cancer with acquired resistance to EGFR tyrosine kinase inhibitors. Oncologist. 2013; 18(11):1214-20.
View in: PubMed

Oxnard GR, Schwartz LH. Response phenotype as a predictive biomarker to guide treatment with targeted therapies. J Clin Oncol. 2013 Oct 20; 31(30):3739-41.
View in: PubMed

Oxnard GR, Jänne PA. Power in numbers: meta-analysis to identify inhibitor-sensitive tumor genotypes. Clin Cancer Res. 2013 Apr 01; 19(7):1634-6.
View in: PubMed

Oxnard GR, Binder A, Jänne PA. New targetable oncogenes in non-small-cell lung cancer. J Clin Oncol. 2013 Mar 10; 31(8):1097-104.
View in: PubMed

Oxnard GR, Lo PC, Nishino M, Dahlberg SE, Lindeman NI, Butaney M, Jackman DM, Johnson BE, Jänne PA. Natural history and molecular characteristics of lung cancers harboring EGFR exon 20 insertions. J Thorac Oncol. 2013 Feb; 8(2):179-84.
View in: PubMed

West H, Oxnard GR, Doebele RC. Acquired resistance to targeted therapies in advanced non-small cell lung cancer: new strategies and new agents. Am Soc Clin Oncol Educ Book. 2013.
View in: PubMed

Oxnard GR. Strategies for overcoming acquired resistance to epidermal growth factor receptor: targeted therapies in lung cancer. Arch Pathol Lab Med. 2012 Oct; 136(10):1205-9.
View in: PubMed

Shinagare AB, Okajima Y, Oxnard GR, Dipiro PJ, Johnson BE, Hatabu H, Nishino M. Unsuspected pulmonary embolism in lung cancer patients: comparison of clinical characteristics and outcome with suspected pulmonary embolism. Lung Cancer. 2012 Nov; 78(2):161-6.
View in: PubMed

Oxnard GR, Morris MJ, Hodi FS, Baker LH, Kris MG, Venook AP, Schwartz LH. When progressive disease does not mean treatment failure: reconsidering the criteria for progression. J Natl Cancer Inst. 2012 Oct 17; 104(20):1534-41.
View in: PubMed

Oxnard GR, Jänne PA. KRAS wild-type lung cancer: a moving target in an era of genotype migration. J Clin Oncol. 2012 Sep 20; 30(27):3322-4.
View in: PubMed

Oxnard GR, Miller VA, Robson ME, Azzoli CG, Pao W, Ladanyi M, Arcila ME. Screening for germline EGFR T790M mutations through lung cancer genotyping. J Thorac Oncol. 2012 Jun; 7(6):1049-52.
View in: PubMed

Rekhtman N, Paik PK, Arcila ME, Tafe LJ, Oxnard GR, Moreira AL, Travis WD, Zakowski MF, Kris MG, Ladanyi M. Clarifying the spectrum of driver oncogene mutations in biomarker-verified squamous carcinoma of lung: lack of EGFR/KRAS and presence of PIK3CA/AKT1 mutations. Clin Cancer Res. 2012 Feb 15; 18(4):1167-76.
View in: PubMed

He M, Capelletti M, Nafa K, Yun CH, Arcila ME, Miller VA, Ginsberg MS, Zhao B, Kris MG, Eck MJ, Jänne PA, Ladanyi M, Oxnard GR. EGFR exon 19 insertions: a new family of sensitizing EGFR mutations in lung adenocarcinoma. Clin Cancer Res. 2012 Mar 15; 18(6):1790-7.
View in: PubMed

Grommes C, Oxnard GR, Kris MG, Miller VA, Pao W, Holodny AI, Clarke JL, Lassman AB. "Pulsatile" high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer. Neuro Oncol. 2011 Dec; 13(12):1364-9.
View in: PubMed

Chaft JE, Oxnard GR, Sima CS, Kris MG, Miller VA, Riely GJ. Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib: implications for clinical trial design. Clin Cancer Res. 2011 Oct 01; 17(19):6298-303.
View in: PubMed

Oxnard GR, Janjigian YY, Arcila ME, Sima CS, Kass SL, Riely GJ, Pao W, Kris MG, Ladanyi M, Azzoli CG, Miller VA. Maintained sensitivity to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer recurring after adjuvant erlotinib or gefitinib. Clin Cancer Res. 2011 Oct 01; 17(19):6322-8.
View in: PubMed

Oxnard GR, Arcila ME, Chmielecki J, Ladanyi M, Miller VA, Pao W. New strategies in overcoming acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer. Clin Cancer Res. 2011 Sep 01; 17(17):5530-7.
View in: PubMed

Chmielecki J, Foo J, Oxnard GR, Hutchinson K, Ohashi K, Somwar R, Wang L, Amato KR, Arcila M, Sos ML, Socci ND, Viale A, de Stanchina E, Ginsberg MS, Thomas RK, Kris MG, Inoue A, Ladanyi M, Miller VA, Michor F, Pao W. Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling. Sci Transl Med. 2011 Jul 06; 3(90):90ra59.
View in: PubMed

Oxnard GR, Zhao B, Sima CS, Ginsberg MS, James LP, Lefkowitz RA, Guo P, Kris MG, Schwartz LH, Riely GJ. Variability of lung tumor measurements on repeat computed tomography scans taken within 15 minutes. J Clin Oncol. 2011 Aug 10; 29(23):3114-9.
View in: PubMed

Oxnard GR, Janjigian YY, Arcila ME, Kris MG, Ladanyi M, Azzoli CG, Miller VA. Maintained sensitivity to EGFR tyrosine kinase inhibitors (TKIs) in EGFR-mutant lung cancers that recur after adjuvant TKI. J Clin Oncol. 2011 May 20; 29(15_suppl):7029.
View in: PubMed

Chaft JE, Oxnard GR, Miller VA, Kris MG, Sima CS, Riely GJ. Disease flare after tyrosine kinase inhibitor (TKI) discontinuation in patients with EGFR-mutant lung cancer and acquired resistance. J Clin Oncol. 2011 May 20; 29(15_suppl):e18001.
View in: PubMed

Arcila ME, Oxnard GR, Nafa K, Riely GJ, Solomon SB, Zakowski MF, Kris MG, Pao W, Miller VA, Ladanyi M. Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay. Clin Cancer Res. 2011 Mar 01; 17(5):1169-80.
View in: PubMed

Oxnard GR, Arcila ME, Sima CS, Riely GJ, Chmielecki J, Kris MG, Pao W, Ladanyi M, Miller VA. Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation. Clin Cancer Res. 2011 Mar 15; 17(6):1616-22.
View in: PubMed

Zhao B, Oxnard GR, Moskowitz CS, Kris MG, Pao W, Guo P, Rusch VM, Ladanyi M, Rizvi NA, Schwartz LH. A pilot study of volume measurement as a method of tumor response evaluation to aid biomarker development. Clin Cancer Res. 2010 Sep 15; 16(18):4647-53.
View in: PubMed

Oxnard GR, Miller VA. Use of erlotinib or gefitinib as initial therapy in advanced NSCLC. Oncology (Williston Park). 2010 Apr 30; 24(5):392-9.
View in: PubMed

Oxnard GR, Schwartz LH. Early changes in tumor size in patients treated for advanced stage nonsmall cell lung cancer do not correlate with survival. Cancer. 2010 Mar 15; 116(6):1615; author reply 1616.
View in: PubMed

Oxnard GR, Zinkus TM, Bazari H, Wolf M. Integrating research training into residency: tools of human investigation. Acad Med. 2009 Sep; 84(9):1295-300.
View in: PubMed

Oxnard GR. False-positive rate of posttherapy positron emission tomography in cervical cancer. JAMA. 2008 Feb 27; 299(8):898; author reply 898.
View in: PubMed

Oxnard GR, Fidias P, Muzikansky A, Sequist LV. Non-small cell lung cancer in octogenarians: treatment practices and preferences. J Thorac Oncol. 2007 Nov; 2(11):1029-35.
View in: PubMed

Oxnard GR. Bevacizumab for non-small-cell lung cancer. N Engl J Med. 2007 Mar 29; 356(13):1373; author reply 1374-5.
View in: PubMed

Oxnard GR, Armato SG, Kindler HL. Modeling of mesothelioma growth demonstrates weaknesses of current response criteria. Lung Cancer. 2006 May; 52(2):141-8.
View in: PubMed

Armato SG, Oxnard GR. The radiologic measurement of mesothelioma. Hematol Oncol Clin North Am. 2005 Dec; 19(6):1053-66, vi.
View in: PubMed

Armato SG, Oxnard GR, Kocherginsky M, Vogelzang NJ, Kindler HL, MacMahon H. Evaluation of semiautomated measurements of mesothelioma tumor thickness on CT scans. Acad Radiol. 2005 Oct; 12(10):1301-9.
View in: PubMed

Oxnard GR, Armato SG, Salgia R, Kindler HL. Development of response criteria for mesothelioma based on a mathematical model. J Clin Oncol. 2005 Jun; 23(16_suppl):7176.
View in: PubMed

Armato SG, Oxnard GR, MacMahon H, Vogelzang NJ, Kindler HL, Kocherginsky M, Starkey A. Measurement of mesothelioma on thoracic CT scans: a comparison of manual and computer-assisted techniques. Med Phys. 2004 May; 31(5):1105-15.
View in: PubMed

Research Departments:

Location

Dana-Farber Cancer Institute
450 Brookline Avenue
Dana 1234
Boston MA, 02215
Get Directions

Top